NCT04532125View on ClinicalTrials.gov

SAD and MAD Study With IV and SC Doses of ARGX-117

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ARGX-117

Subjects treated with ARGX-117

OTHER

Placebo

Subjects treated with placebo

BIOLOGICAL

ARGX-117 + rHuPH20

Subjects treated with ARGX-117 + rHuPH20

OTHER

placebo + rHuPH20

Subjects treated with placebo + rHuPH20

BIOLOGICAL

ARGX-117 PH20 SC

Subjects treated with ARGX-117 PH20 SC

OTHER

Placebo PH20 SC

Subjects treated with placebo PH20 SC

Trial Locations (1)

Unknown

Investigator Site 1, Groningen

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT04532125 - SAD and MAD Study With IV and SC Doses of ARGX-117 | Biotech Hunter | Biotech Hunter